There has been a good deal of optimism about the potential efficacy and safety of the radioisotope-labeled product known as prostate-specific membrane antigen-linked lutetium-177 (177Lu-PSMA) in the treatment of very late stage prostate cancer. A newly published paper by a German research group (Baum et al.) in the Journal of Nuclear Medicine has now provided […]![]()
